Direct Interactions With Cancer-Associated Fibroblasts Lead to Enhanced Pancreatic Cancer Stem Cell Function.


Journal

Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542

Informations de publication

Date de publication:
Mar 2019
Historique:
pubmed: 13 2 2019
medline: 3 9 2019
entrez: 13 2 2019
Statut: ppublish

Résumé

Cancer-associated fibroblasts (CAFs) play an important role in the progression of pancreatic ductal adenocarcinoma (PDAC) by promoting tumor cell migration and drug resistance. We determined the impact of CAFs on PDAC cancer stem cells (CSCs). Fibroblast cell lines from patients' tumors were cocultured with PDAC cells and examined for clonogenic growth and self-renewal using colony-forming assays and migration in vitro. Changes in the frequency of CSCs was determined by flow cytometry. The effect of integrin-focal adhesion kinase (FAK) signaling on CAF-mediated clonogenic growth was evaluated using short hairpin RNAs against β1 integrin and FAK as well as a small-molecule FAK inhibitor. Cancer-associated fibroblasts enhanced PDAC clonogenic growth, self-renewal, and migration that was associated with an increase in the frequency of CSCs. These fibroblast cells were activated by PDAC cells and increased collagen synthesis resulting in FAK activation in PDAC cells. Knockdown of β1-integrin and FAK or the inhibition of FAK kinase activity in PDAC cells abrogated the impact of CAFs on clonogenic growth. Therefore, CAFs enhance PDAC clonogenic growth, self-renewal, and the frequency of CSCs through type I collagen production that enhances integrin-FAK signaling in PDAC cells.

Identifiants

pubmed: 30747824
doi: 10.1097/MPA.0000000000001249
pmc: PMC6411432
mid: NIHMS1517406
doi:

Substances chimiques

Integrin beta1 0
Focal Adhesion Kinase 1 EC 2.7.10.2
PTK2 protein, human EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

329-334

Subventions

Organisme : NCI NIH HHS
ID : K24 CA198315
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA193887
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA150142
Pays : United States

Références

Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
Nat Cell Biol. 2010 May;12(5):468-76
pubmed: 20418870
Histopathology. 2009 Mar;54(4):442-51
pubmed: 19309396
Transl Oncol. 2008 Mar;1(1):14-8
pubmed: 18607507
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Int J Cancer. 2011 Nov 15;129(10):2315-27
pubmed: 21792897
Cancer Res. 2011 Jan 15;71(2):614-24
pubmed: 21224357
Endocr Relat Cancer. 2013 Jan 07;20(1):1-12
pubmed: 23111755
J Vis Exp. 2010 Sep 26;(43):
pubmed: 20972397
Mol Cells. 2013 Aug;36(2):138-44
pubmed: 23839513
Oncotarget. 2016 Jan 26;7(4):4183-94
pubmed: 26716653
Blood. 2014 Jan 30;123(5):725-33
pubmed: 24345755
J Surg Oncol. 2017 Jul;116(1):7-15
pubmed: 28605029
J Cell Biol. 2017 Nov 6;216(11):3799-3816
pubmed: 29021221
Mol Cell. 2001 Jun;7(6):1267-78
pubmed: 11430829
Int J Oncol. 2017 Jan;50(1):121-128
pubmed: 27878234
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Semin Cancer Biol. 2012 Oct;22(5-6):396-403
pubmed: 22554795
BMC Cancer. 2011 Jun 13;11:245
pubmed: 21668992
J Natl Cancer Inst. 2010 Mar 3;102(5):340-51
pubmed: 20164446
Clin Cancer Res. 2009 Aug 15;15(16):5060-72
pubmed: 19671845
PLoS One. 2017 Jul 10;12(7):e0180181
pubmed: 28692661
Cancer Discov. 2016 Aug;6(8):886-99
pubmed: 27184426
Am J Pathol. 2002 May;160(5):1787-98
pubmed: 12000730
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Cancer Biol Ther. 2008 Jun;7(6):882-8
pubmed: 18344687
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
PLoS One. 2016 Aug 03;11(8):e0159912
pubmed: 27487118
Cancer Sci. 2013 Feb;104(2):157-64
pubmed: 23121112
Cancer Res. 2006 Oct 1;66(19):9339-44
pubmed: 16990346
Head Neck. 2005 Sep;27(9):794-800
pubmed: 15952193
Mol Cancer Ther. 2009 Feb;8(2):310-4
pubmed: 19174553
Cancer Res. 2008 Feb 1;68(3):937-45
pubmed: 18245497
Nat Commun. 2014 Mar 25;5:3472
pubmed: 24668028
Breast Cancer Res. 2007;9(1):R19
pubmed: 17311675
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Gastroenterology. 2013 Jun;144(6):1210-9
pubmed: 23622130
Cancer Res. 2006 Sep 1;66(17):8319-26
pubmed: 16951136
J Clin Oncol. 2015 Dec 20;33(36):4284-92
pubmed: 26527777

Auteurs

Anirban Maitra (A)

Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX.

Michael G Goggins (MG)

Departments of Pathology and.

James R Eshelman (JR)

Departments of Pathology and.

Christopher L Wolfgang (CL)

Surgery, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH